---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134970"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:02:59.939183+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh

## Summary
- Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.
- Net proceeds to fund onvansertib clinical costs for RAS-mutated metastatic colorectal cancer (mCRC).
- New mutual fund and healthcare dedicated investors participated; existing investors also supported.
- Expected close Dec 11, 2024; 90-day lock-up for directors and officers on share sales.
- TD Cowen lead bookrunner; William Blair, H.C. Wainwright, Craig-Hallum also underwriters.

## SEC filing metadata
- accession: 0000950170-24-134970
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/0000950170-24-134970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/crdf-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134970
- JSON: https://secwatch.observer/filing/0000950170-24-134970.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.